Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

@article{Hancock2004AdjuvantII,
  title={Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.},
  author={Barry William Hancock and Keith Wheatley and Sam Harris and Natalie Ives and Georgina Harrison and Janet M. Horsman and Mark R. Middleton and Nicholas Thatcher and Paul C. Lorigan and Jerry R Marsden and L M Burrows and Martin Gore},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 1},
  pages={53-61}
}
PURPOSE To evaluate low-dose extended duration interferon alfa-2a as adjuvant therapy in patients with thick (> or = 4 mm) primary cutaneous melanoma and/or locoregional metastases. PATIENTS AND METHODS In this randomized controlled trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared with that of no further treatment in radically resected stage… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

Metastatic melanoma – a review of current and future drugs

Drugs in context • 2012
View 14 Excerpts
Highly Influenced

Adjuvant Therapy: Melanoma

Journal of skin cancer • 2011
View 5 Excerpts
Highly Influenced

Indications and options for systemic therapy in melanoma.

The Surgical clinics of North America • 2014
View 4 Excerpts
Highly Influenced

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Annals of oncology : official journal of the European Society for Medical Oncology • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…